

# ANTIBODY Fc

LINKING ADAPTIVE AND  
INNATE IMMUNITY

MARGARET E. ACKERMAN  
FALK NIMMERJAHN




# ANTIBODY Fc: LINKING ADAPTIVE AND INNATE IMMUNITY

Margaret E. Ackerman

Thayer School of Engineering, Dartmouth College, USA

Falk Nimmerjahn

Institute of Genetics, University of Erlangen-Nurnberg, Erlangen, Germany



AMSTERDAM • BOSTON • HEIDELBERG • LONDON  
NEW YORK • OXFORD • PARIS • SAN DIEGO  
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO  
Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier  
32 Jamestown Road, London NW1 7BY, UK  
225 Wyman Street, Waltham, MA 02451, USA  
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA

First edition 2014

Copyright © 2014 Elsevier Inc. All rights reserved

No other part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: [permissions@elsevier.com](mailto:permissions@elsevier.com). Alternatively, visit the Science and Technology Books website at [www.elsevierdirect.com/rights](http://www.elsevierdirect.com/rights) for further information

#### Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein.

Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

#### British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

#### Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-12-394802-1

For information on all Academic Press publications  
visit our website at [elsevierdirect.com](http://elsevierdirect.com)

Typeset by MPS Limited, Chennai, India  
[www.adi-mps.com](http://www.adi-mps.com)

Printed and bound in China

14 15 16 17 18 10 9 8 7 6 5 4 3 2 1



Working together  
to grow libraries in  
developing countries

[www.elsevier.com](http://www.elsevier.com) • [www.bookaid.org](http://www.bookaid.org)

# ANTIBODY F<sub>c</sub>: LINKING ADAPTIVE AND INNATE IMMUNITY

---

# List of Contributors

---

- Shannon A. Allen** Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Robert M. Anthony** Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Kavitha Baruah** University of Oxford, Oxford, United Kingdom
- Carolyn M. Black** National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
- Wim K. Bleeker** Genmab, Utrecht, The Netherlands
- Silvia Bolland** National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
- Menna R. Clatworthy** University of Cambridge School of Clinical Medicine, Cambridge, UK; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- Mattias Collin** Lund University, Lund, Sweden
- Max Crispin** University of Oxford, Oxford, United Kingdom
- Andreas Diefenbach** Department of Medical Microbiology and Hygiene (IMMH), University of Freiburg, Freiburg, Germany
- Victor Raúl Gómez Román** International Vaccine Institute, Seoul, Korea
- Scott B. Halstead** Dengue Vaccine Initiative, International Vaccine Institute, Seoul, Korea
- Ann J. Hessel** Oregon Health & Science University, Beaverton, OR, USA
- Thomas J. Hope** Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Joseph U. Igiertseme** National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, USA; Morehouse School of Medicine, Atlanta, GA, USA
- Roy Jefferis** University of Birmingham, Birmingham, United Kingdom
- Jörg Köhla** University of Lübeck, Lübeck, Germany; Cincinnati Children's Hospital and University, Cincinnati, OH, USA
- Mogens Kilian** Aarhus University, Aarhus, Denmark
- Margaret A. Lindorfer** University of Virginia Charlottesville, VA, USA
- Luisa Martinez-Pomares** Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom
- Brian Moldt** The Scripps Research Institute, La Jolla, CA, USA
- Joseph C. Murray** Georgetown University Medical Center, Washington, DC, USA
- Falk Nimmerjahn** University of Erlangen-Nürnberg, Erlangen, Germany
- Marije B. Overdijk** Genmab, Utrecht, The Netherlands
- Annette Oxenius** Institute of Microbiology, ETH Zürich, Zürich, Switzerland
- Paul W.H.I. Parren** Genmab, Utrecht, The Netherlands
- Theo Rispens** University of Amsterdam, The Netherlands
- Christopher N. Scanlan** University of Oxford, Oxford, United Kingdom
- Peter Sun** National Institutes of Health, Rockville, MD, USA
- Ronald P. Taylor** University of Virginia School of Medicine, Charlottesville, VA, USA
- Sandra Verploegen** Genmab, Utrecht, The Netherlands
- Gestur Vidarsson** University of Amsterdam, The Netherlands

**Elizabeth R. Walsh** National Institutes of Health,  
Rockville, MD, USA

**Stefan S. Weber** Institute of Microbiology, ETH  
Zürich, Zürich, Switzerland

**George J. Weiner** University of Iowa, Iowa City,  
IA, USA

**Louis M. Weiner** Georgetown University Medical  
Center, Washington, DC, USA

**Xiaojie Yu** University of Oxford, Oxford, United  
Kingdom

**Xiaoping Zhu** University of Maryland, College  
Park, MD, USA

# Short Contents

---

## I

---

### EFFECTOR MECHANISMS

1. Antibody-Dependent Cellular Cytotoxicity (ADCC) 1
2. Antibody-Dependent Cellular Phagocytosis and Its Impact on Pathogen Control 29
3. Interactions Between the Complement System and Fc $\gamma$  Receptors 49

## 2

---

### EFFECTOR CELLS

4. Natural Killer Cells 75
5. Phagocytes and Immunoglobulins 94
6. B Cells 115

## 3

---

### FcR

7. Structural Recognition of Immunoglobulins by Fc $\gamma$  Receptors 131
8. Fc $\gamma$ Rs Across Species 145

## 4

---

### VARIABILITY OF THE Fc DOMAIN

9. Human IgG Subclasses 159
10. Antibody Glycosylation 179

## 5

---

### GENETIC ASSOCIATIONS

11. Activating and Inhibitory Fc $\gamma$ Rs in Autoimmune Disorders 195
12. Fc $\gamma$  Receptor Polymorphisms and Susceptibility to Infection 216
13. Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer 239

## 6

---

### EVOLVING AREAS

14. No Mechanism is an Island 257
15. Fc Receptor-Dependent Immunity 268
16. Fc $\gamma$  Receptors as Therapeutic Targets 283
17. Fc Protein Engineering 297
18. Bacterial Modulation of Fc Effector Functions 317
19. Pathogenic Exploitation of Fc Activity 333
20. Mechanisms of Immunoglobulin-Mediated Mucus Entrapment of Pathogens at Various Mucosal Surfaces 351

# Contents

---

## List of Contributors xi

## I

### EFFECTOR MECHANISMS

#### 1 Antibody-Dependent Cellular Cytotoxicity (ADCC)

VICTOR RAÚL GÓMEZ ROMÁN, JOSEPH C. MURRAY AND  
LOUIS M. WEINER

Brief History of ADCC	1
Effector Cells	2
Receptors Involved	3
Mechanisms of ADCC	4
ADCC in Monoclonal Antibody Therapy of Cancer	9
ADCC in Infectious Disease: A Correlate of Protection?	14
Rational Modification of ADCC Activity	18
Enhancing the Link between ADCC and Adaptive Immunity	19
Perspectives: Future Directions	22
Acknowledgments	22
References	22

#### 2 Antibody-Dependent Cellular Phagocytosis and Its Impact on Pathogen Control

STEFAN S. WEBER AND ANNETTE OXENIUS

Introduction	29
Phagocytic Cells and Their Fcγ Receptors	29
Fcγ Receptor-Mediated Phagocytosis by Phagocytes	31
Role of FcγR-Mediated Phagocytosis for Pathogen Uptake, Cellular Localization, and Pathogen Control	33

Concluding Remarks 39

References 41

#### 3 Interactions Between the Complement System and Fcγ Receptors

MARGARET A. LINDORFER, JÖRG KÖHL AND  
RONALD P. TAYLOR

Preliminary Comments	49
Complement Fragment C3b Mediates Binding of IgG Immune Complexes to Primate Erythrocytes: Immune Adherence	51
Complement Fragment C3d Mediates Binding of Substrates to CR2 on B Cells: Antigen Trafficking and Its Significance in HIV Disease	55
Cooperation/Synergy between Fcγ Receptors and Complement Receptors on Effector Cells	58
Cross-Talk between the C5a Receptor and FcγR on Effector Cells	63
Concluding Remarks	68
Abbreviations	69
References	69

## 2

### EFFECTOR CELLS

#### 4 Natural Killer Cells

ANDREAS DIEFENBACH

Inhibitory Receptor Modules Inform a Useful and Self-Tolerant NK Cell Repertoire	76
Activating Immunoreceptors Mediate NK Cell Recognition of Tumors and Infected Cells	78
Adaptive Features of NK Cells	81
References	84



## 5 Phagocytes and Immunoglobulins

LUISA MARTINEZ-POMARES

- Antibodies in the Context of Innate and Acquired Immune Recognition 95
- General Characteristics of Mononuclear Phagocytes: Macrophages, Monocytes, and Dendritic Cells 95
- General Characteristics of Granulocytes 96
- Opsonic and Non-Opsonic Recognition in Phagocytes 99
- Non-Opsonic Recognition: Pattern Recognition Receptors 99
- Phagocyte Activation in Response to Non-Opsonic Recognition 99
- Opsonic Recognition: FcRs and Complement Receptors 101
- Phagocyte Cooperation during Inflammation 102
- Phagocytosis 104
- Antigen Presentation by DCs, Role of FcγRs 107
- Collaboration Between FcR and Non-Opsonic Receptors 108
- Concluding Remarks 109
- References 109

## 6 B Cells

ELIZABETH R. WALSH AND SILVIA BOLLAND

- B Cell Development and Selection in the Bone Marrow 115
- B Cell Selection, Activation, and Tolerance in the Peripheral Immune System 116
- Generation of Plasma Cells and Memory B Cells in the Germinal Center 117
- FcγRIIB Regulates B-Cell Activation and Apoptosis 120
- FcγRIIB Inhibits Autoantibody Production 121
- FcγRIIB as a Regulator of Long-Term Survival of Plasma Cells in the Bone Marrow 125
- References 126

## 3

### FcR

#### 7 Structural Recognition of Immunoglobulins by Fcγ Receptors

PETER SUN

- Introduction 131
- Structures of Fcγ Receptors 131
- Structure of the IgG Fc Domain 134
- Structure of FcγRIII–Fc Complex 134

- FcγRIII–Fc Binding Interface 136
- FcγR Specificities for IgG Subclasses 137
- Fc Receptor Isoform Affinities to IgG 138
- Influence of FcR Polymorphism on IgG Recognition 138
- Role of Fc Glycosylation in the Recognition of Antibodies by Fcγ Receptors 139
- Recognition of Fc Receptors by Pentraxins 140
- Conclusions 141
- References 141

#### 8 FcγRs Across Species

BRIAN MOLDT AND ANN J. HESSELL

- Introduction 145
- Human FcγRs 146
- Mouse FcγRs 148
- Human *Versus* Mouse FcγRs 149
- Macaque FcγRs 151
- Human *Versus* Macaque FcγRs 152
- Conclusions 155
- Acknowledgments 155
- References 155

## 4

### VARIABILITY OF THE Fc DOMAIN

#### 9 Human IgG Subclasses

THEO RISPENS AND GESTUR VIDARSSON

- Introduction: Immunoglobulins and Humoral Immunity 159
- Genetics 159
- Structure 162
- Binding to Effector Molecules 166
- IgG Antibody Responses 169
- Therapeutic Considerations 171
- Acknowledgment 172
- References 172

#### 10 Antibody Glycosylation

XIAOJIE YU, KAVITHA BARUAH, CHRISTOPHER N. SCANLAN, AND MAX CRISPIN

- Human Antibody: An Overview of Structure and Function 179
- Human IgG Fc Structure and Function 180

Human IgG Fc Glycosylation	181
Role of IgG Fc Glycosylation in Fc Structure	183
Activities of IgG Glycoforms	184
Glycan Engineering of Antibodies	187
Endoglycosidases in Immune Evasion and Therapeutics	189
Variations of Antibody Glycosylation in Disease	190
Conclusion and Perspectives	190
References	190

## 5

## GENETIC ASSOCIATIONS

### 11 Activating and Inhibitory FcγRs in Autoimmune Disorders

FALK NIMMERJAHN

Introduction	195
A Question of Balance: Co-expression of Activating and Inhibitory Fc Receptors	196
Establishing the Threshold for Cell Activation: Activating and Inhibitory Fc Receptor Signaling	197
Signaling Pathways of Activating Fc Receptors	197
Inhibitory Signaling Pathways	198
Disturbing the Threshold: Horror Autotoxicus	199
Changing the Expression Level of the Inhibitory Receptor on B Cells	199
FcγRIIB as a Regulator of Dendritic Cell Activity	201
The Role of FcγRIIB in the Efferent Response: Controlling Innate Immune Effector Cell Activation	202
The Activating Fc Receptors in the Efferent Response	203
Exogenous Factors Modulating the Balance: Cytokines and Sugar	205
Regaining the Balance: Therapeutic Interventions that Modulate FcR Expression	206
Conclusions	207
Acknowledgments	208
References	208

### 12 Fcγ Receptor Polymorphisms and Susceptibility to Infection

MENNA R. CLATWORTHY

Introduction	217
The Fcγ Receptor Family Genes	218
FcγR Distribution and Function	219
Genetic Variation in Human FcγRs	219

FcγRs and Infection: Evidence Base	221
FcγRs and Defense against Infection	222
Conclusions	231
Acknowledgments and Funding	232
References	232

### 13 Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer

MARIJE B. OVERDIJK, SANDRA VERPLOEGEN, WIM K. BLEEKER, AND PAUL W.H.I. PARREN

Mechanisms of Action of Monoclonal Antibodies in Oncology	239
Development of Therapeutic Monoclonal Antibodies for the Treatment of Cancer	239
Fc-Mediated Effector Functions, Preclinical Data	242
Role for FcγR-Mediated Effector Functions, Clinical Data	243
Polymorphisms in FcγRs	244
Impact of FcγR Polymorphisms on mAb Treatment, Preclinical <i>In Vitro</i> Data	245
Impact of FcγR Polymorphisms in mAb Treatment, Clinical Data	245
Opportunities to Enhance FcγR-Mediated Effector Functions	250
Future Perspectives	251
References	251

## 6

## EVOLVING AREAS

### 14 No Mechanism is an Island

GEORGE J. WEINER

Introduction	257
<i>In Vitro</i> Analysis	257
Animal Models	259
Clinical Trials	260
Individual Mechanisms of Action	262
Interacting Mechanisms	263
Conclusion	263
References	264

### 15 Fc Receptor-Dependent Immunity

JOSEPH U. IGIETSEME, XIAOPING ZHU AND CAROLYN M. BLACK

Fc Receptors and Signaling Mechanisms in Immune Effector Cells	269
--	-----

Contribution of FcR-Mediated Immune Effector Functions of Antibodies to Protective Acquired Immunity 272	Classical Pathway of Complement Activation 308
The Immune Effector Mechanisms of FcR-Dependent Functional Processes and Their Applications in Immunotherapy and Immunomodulation 276	Immunogenicity and Adverse Events 309
Acknowledgments 280	Human IgG-Fc Binding Ligands in Nature 310
References 280	Concluding Remarks 310
	References 311
16 Fc $\gamma$ Receptors as Therapeutic Targets	18 Bacterial Modulation of Fc Effector Functions
ROBERT M. ANTHONY	
Introduction 283	Introduction 317
The A/I Ratio 284	Immunoglobulin-Binding Proteins 317
Fc Glycan Control of Fc $\gamma$ R Interactions 285	Immunoglobulin Proteases 322
Activating and Inhibitory Fc $\gamma$ R Expression 286	Immunoglobulin Glycan Hydrolases 326
Anti-Inflammatory IgG Modulates Fc $\gamma$ R Expression 287	Concluding Remarks 328
Fc $\gamma$ R Regulation During Autoimmune Disease 287	Acknowledgments 328
Fc $\gamma$ R Regulation During Infection 288	References 328
Fc $\gamma$ R Regulation During Cancer 288	
Engineering IgG Immune Responses 289	19 Pathogenic Exploitation of Fc Activity
Targeting Fcs to Fc $\gamma$ Rs 290	SCOTT B. HALSTEAD
Engineering the Fc Peptide Backbone 290	
Outlook and Perspectives 291	Introduction 333
References 292	ADE in Viruses 334
	ADE in Protozoan Parasites of Macrophages: <i>Leishmania</i> 341
17 Fc Protein Engineering	ADE in Other Intracellular Parasites and Bacteria 344
ROY JEFFERIS	Concluding Thoughts 345
	References 345
Introduction 297	
The IgG Subclasses 298	20 Mechanisms of Immunoglobulin-Mediated Mucus Entrapment of Pathogens at Various Mucosal Surfaces
IgG-Fc Binding Ligand: An Overview 299	SHANNON A. ALLEN AND THOMAS J. HOPE
Evaluation of IgG-Fc Engineered Proteins 300	
IgG <sub>1</sub> and IgG <sub>3</sub> Binding and Activation of Fc $\gamma$ R 301	Introduction 351
IgG <sub>2</sub> Binding and Activation of Fc $\gamma$ R 303	Structure of Mucus 352
IgG <sub>4</sub> Binding and Activation of Fc $\gamma$ R 304	Mechanisms of Immunity at Mucosal Surfaces 352
The Neonatal Receptor Fc $\gamma$ Rn: Transcytosis and Catabolism 305	Summary 355
	Acknowledgments 356
	References 356
	Index 359

# Antibody-Dependent Cellular Cytotoxicity (ADCC)

Victor Raúl Gómez Román<sup>a,\*</sup>, Joseph C. Murray<sup>b,\*</sup> and Louis M. Weiner<sup>b</sup>


<sup>a</sup>International Vaccine Institute, Seoul, Korea, <sup>b</sup>Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown Medical Center, Washington, DC, USA

## BRIEF HISTORY OF ADCC

In the 1960s, several independent laboratory observations indicated that cells could be killed by other cells, yet the mechanisms of killing were unknown. Several hypotheses were formulated and experiments were conducted paving the way for the discovery and characterization of what we now know as cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. However, early experiments pointed to the hypothesis that immune serum was in some cases necessary for some types of effector cells to mediate killing of target cells. In 1965, Erna Möeller, a researcher working at the Karolinska Institute, showed that incubation of mouse tumor target cells with heat-inactivated anti-serum from rabbits immunized with these tumor cells, followed by incubation with lymphoid cells from unimmunized mice, resulted in cytotoxicity.<sup>1</sup> Such cytotoxicity required contact or “serum-induced

aggregation” between the tumor targets and the lymphoid effectors. Experiments were subsequently performed to identify the aggregating and cytotoxicity-inducing factor contained in serum. In 1970, MacLennan, Loewi, and Harding, researchers working at the Canadian Red Cross Memorial Hospital, reported that the serum factor required for this type of cell-mediated cytotoxicity was an immunoglobulin with the “chemical properties of IgG.”<sup>2</sup> Subsequent experiments confirmed this finding by showing that the antibody required belonged to the IgG class and that the mechanism of antibody-dependent killing of target cells by serum factors did not require the heat-labile components of complement, as heat inactivation of serum maintained the killing effect.<sup>2</sup> The phenomenon acquired the name of “antibody-dependent lymphocyte-mediated cytotoxicity”<sup>3</sup> and gradually became known as “antibody-dependent cell-mediated cytotoxicity,” or ADCC. The three basic components of ADCC were recognized as being effector cells, antibodies, and target cells coated with antigen. “Targets” could refer to

\* Corresponding Author



**FIGURE 1.1 Effector cells and targets.** ADCC involves the interplay between a granular effector cell and a target cell expressing antigens on its surface. The granular effector cell must express Fc receptors on its surface for ADCC to occur.

cells expressing tumor, viral, or bacterial antigens; therefore, ADCC became known as an immune mechanism that could be potentially protective against certain types of cancers as well as infectious diseases. Considerable progress has been made in characterizing the effector cells and the receptors involved in this phenomenon, and ADCC can now be defined as the immune mechanism through which Fc-receptor-bearing effector cells can kill target cells that have surface antigens complexed with antibody (Figure 1.1).

## EFFECTOR CELLS

Although initial experiments focused on large granular lymphocytes as the main effector cells mediating ADCC, several groups have now characterized the types of cells that can mediate ADCC effector function. Table 1.1

describes the various types of effector cells that have been shown to mediate ADCC. Three common characteristics of these cells are that they are all leukocytes, they contain granules, and they express Fc receptors. Mononuclear leukocytes (NK cells, macrophages,  $\gamma\delta$  T cells) and polymorphonuclear leukocytes (neutrophils, basophils, eosinophils) can both mediate ADCC.<sup>4</sup> This diversity of effectors is worth emphasizing, as a significant proportion of ADCC experiments reported in the scientific literature are either “NK-centric” or focused on the use of the peripheral blood mononuclear cell (PBMC) fraction to obtain effector cells. This unintentional experimental bias tends to overlook the role of neutrophils and other polymorphonuclear leukocytes (PMNs or PMLs); it is probably a consequence of both the relative ease of working with peripheral NK cells and the practical difficulties associated with working with PMNs, which are rather short lived

TABLE 1.1 Peripheral Blood Effector Cells and Fc Receptors Involved in ADCC

Leukocyte Fraction	Effectors	Predominant Fc Receptors	Refs.
PBMC	NK cells	FcγRIIIA/CD16	Wallace et al. <sup>4</sup>
	Monocytes/macrophages	FcγRI/CD64 FcγRII/CD32	Wallace et al., <sup>4</sup> Tudor and Bomsel <sup>5</sup>
	γδ T cells (subset)	FcγRIIIA/CD16	Chen and Freedman <sup>120</sup>
PMN	Granulocytes (neutrophils, basophils, eosinophils)	FcγRII/CD32 FcγRIIIb/CD16b FcαRI/CD89	Wallace et al., <sup>4</sup> Horner et al. <sup>6</sup>

and may require isolation through cumbersome Percoll-gradient procedures or hypotonic lysis steps. While the effector cell phenotype of NK cells, phagocytes, and B are discussed in detail elsewhere in this book, cells contained in the PMN fraction may be equally important effectors involved in Fc-mediated functions, including ADCC.

## RECEPTORS INVOLVED

Three types of Fc receptors are involved in mediating IgG-dependent ADCC: FcγRI (CD64), FcγRII (CD32), and FcγRIIIA (CD16). Of these, FcγRIIIA (CD16) is often invoked as the main receptor involved, as it is expressed predominantly by NK cells (Table 1.1); however, *in vitro* evidence indicates that monocytes and granulocytes can mediate equally potent ADCC via other Fc receptors.<sup>4-6</sup> In cancer and infectious disease research, all three FcγRs have been shown to mediate ADCC. Natural polymorphisms in the Fc receptors have been shown to have a clear impact on ADCC *in vitro* and an effect on ADCC-dependent cancer immunotherapy. Additionally, IgA-dependent ADCC has also been described in some models and is dependent on the Fc alpha receptor (FcαR, CD89), which is expressed primarily on PMN and monocytes (Table 1.1).

Our knowledge of Fc-receptor expression and ADCC function to date has been limited to the study of either immortalized effector cell lines or fresh effector cells circulating in peripheral blood. Less is known about Fc-receptor expression in cells residing in mucosal tissues, which represent the first line of defense against invading pathogens. For example, a recent study examining Fc-receptor expression in a limited number of patients ( $n=5$ ) showed that CD16, CD32, and CD64 expression was virtually nonexistent on rectal macrophages compared to the levels of expression observed on peripheral blood monocytes.<sup>7</sup> Vaginal macrophages from the same patients, however, expressed very high levels of CD16. This may have important implications for ADCC, as it could suggest that ADCC (and other Fc-receptor-dependent mechanisms of immunity) may be relevant as a first line of mucosal defense in some compartments but not in others. In this regard, several studies have examined the role of mucosal antibody in mediating ADCC *in vitro* using effector cell lines or fresh effector cells derived from peripheral blood. In contrast, less is known about the ADCC function of effector cells recovered from mucosal tissues, and defining the expression of Fc receptors across mucosal tissues and assessing their *ex vivo* ADCC function might yield insights into the spatial and temporal role of ADCC in infection and immunity.



## MECHANISMS OF ADCC

### Recognition of the Target Cell and Cross-Linking of the Fc Receptor on the Effector Cell

An obvious prerequisite for ADCC to occur is the interaction of antibody bound to the target cell with Fc receptors on the effector cell. This interaction is both regulated and facilitated by conformational changes that occur in the antibody molecule only after it has bound to its cognate antigen (Figure 1.1). After binding to surface antigens on the target cell, conformational changes occur in the Fc region of the antibody, which result in its increased affinity for a single Fc receptor on the effector cell.<sup>8</sup> Glycosylation of the Fc region also plays an important role in modulating the affinity of antibody for Fc receptors; in particular, antibodies that are heavily fucosylated (during posttranslational modifications within the B cell) have decreased affinity for Fc $\gamma$ RIIIA (CD16), whereas removal of fucose enhances their affinity for Fc $\gamma$ RIIIA and their ability to mediate ADCC.<sup>9</sup> Recent evidence indicates that binding between IgG and Fc $\gamma$ RIIIA involves tight carbohydrate-carbohydrate interactions that are weakened or obliterated when IgG is fucosylated.<sup>10</sup>

Compared to small, soluble antigens, the relatively larger size of tumors or virally infected cells coated with several antibody molecules on their surface can facilitate physical rearrangements and interactions between Fc receptors present on effector cells (Figure 1.2A). These interactions are often referred to as Fc-receptor ligation, agglutination, aggregation, or cross-linking. The main model to study “ADCC-like” signal transduction pathways relies on the assumption that the first step in generating an ADCC response is the ligation or cross-linking of Fc receptors on the surface of the effector cell as facilitated by a large, “particulate” antigen such as a viral-infected cell coated with surface antigen-specific antibody


(Figure 1.2A). Experimentally, to simulate particulate antigen-induced Fc-receptor cross-linking, many researchers incubate NK cells with Fc $\gamma$ RIIIA-specific antibodies, followed by incubation with a secondary antibody (Figure 1.2B).<sup>11</sup> Another method of simulating antigen-induced Fc-receptor cross-linking is by “reverse ADCC,” an experimental setup in which the polarity of the bridging antibody is reversed (Figure 1.2C).<sup>12</sup> Using these two CD16-cross-linking simulation strategies, ADCC-like signal transduction pathways have been dissected in both human and murine NK cells.

### Downstream Signals in the Effector Cell

For ADCC to occur, molecular signals must also be transduced when an Fc $\gamma$ R-bearing effector cell recognizes an antibody-coated target cell.<sup>13–15</sup> Much of what we know about ADCC signal transduction is based on experiments using Fc $\gamma$ RIIIA-bearing NK cells as effector cells. Less is known about signaling in other effector cells expressing other Fc $\gamma$ Rs.

In the current signaling model, the gamma ( $\gamma$ ) subunit associated with the Fc $\gamma$ RIIIA receptor plays a crucial role in signaling (Figure 1.3). It contains immunoreceptor tyrosine-based activation motifs (ITAMs), which are consensus sequences containing tyrosine residues that can be phosphorylated. ITAMs do not have intrinsic tyrosine kinase activity; instead, they become phosphorylated by cellular src kinases upon Fc $\gamma$ RIIIA cross-linking. Phosphorylated ITAMs recruit the spleen tyrosine kinase (Syk) protein, which binds to the ITAMs via its SH2 domains and becomes activated (Figure 1.3). Recruitment and activation of Syk triggers three main pathways involved in ADCC: phospholipase C-gamma pathway (PLC- $\gamma$ ), phosphatidylinositol 3-kinase (PI-3K) pathway, and Vav/Rho-family G-proteins pathway.

The PLC- $\gamma$  pathway involves the Syk-dependent phosphorylation of the PLC- $\gamma$  isozymes. Activated PLC- $\gamma$  cleaves membrane




**FIGURE 1.2 Antibody and Fc $\gamma$ R ligation.** ADCC involves cross-linking Fc receptors on the surface of effector cells. (A) The particulate nature of antibody complexed to antigens expressed on the surface of a target cell facilitates the physical rearrangement of Fc receptors, bringing them closer to each other and inducing their cross-linking (represented here by a black burst symbol). (B) ADCC in human NK cells can be simulated *in vitro* by incubating human NK effector cells with a mouse anti-human Fc $\gamma$ RIIIA (mouse anti-human CD16) antibody (blue), followed by incubation with a secondary antibody (red), such as goat anti-mouse IgG. Addition of the secondary antibody will facilitate physical interactions between CD16 molecules, leading to their cross-linking. (C) ADCC in human NK cells can also be simulated *in vitro* via “reverse ADCC”—that is, by first incubating human NK effector cells with a mouse anti-human Fc $\gamma$ RIIIA (mouse anti-human CD16) antibody (blue), followed by incubation with a mouse target cell expressing Fc $\gamma$ RI receptors (gray). The particulate nature of the target cell will also facilitate physical interactions between CD16 molecules, leading to their cross-linking. Note the reversal in antibody polarity between (A) and (C). E, effector cell. T, target cell.

phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) to generate inositol-1,4,5-trisphosphate (IP<sub>3</sub>) and diacylglycerol (DAG). IP<sub>3</sub> triggers an increase in intracellular free calcium, which is required for cytotoxic granule mobilization and exocytosis. DAG activates protein kinase C (PKC), which is necessary for other NK cell functions not directly related to ADCC. The PLC- $\gamma$  pathway is required for ADCC function and can be blocked by herbimycin A, an antibiotic that inhibits tyrosine kinase activity and ADCC.

The PI-3K pathway involves the Syk-dependent activation of PI-3K. PI-3K is a heterodimer composed of an 85-kDa adaptor protein (facilitates interactions with other tyrosine kinases) and a 110-kDa catalytic subunit. PI-3K phosphorylates membrane PIP<sub>2</sub> into membrane phosphatidylinositol 3,4,5-trisphosphate (PIP<sub>3</sub>). PIP<sub>3</sub> mediates recruitment of pleckstrin homology (PH) domain-containing signaling proteins—that is, proteins (such as PLC- $\gamma$ ) that can be recruited to the membrane through binding





**FIGURE 1.3 ADCC signaling pathways.** ADCC mediated by NK cells involves three main signaling pathways. Following CD16 cross-linking, src kinases are activated and phosphorylate the ITAMs on the  $\gamma$  subunits associated with CD16. This is followed by recruitment of Syk and subsequent activation of the PLC- $\gamma$  pathway, the PI-3K pathway and the Vav/Rho-family G-proteins pathway. The concerted action of these pathways leads to granule mobilization and exocytosis toward the target cell.

to membrane-bound  $\text{PIP}_3$ . Recruitment of PH domain-containing proteins to the membrane facilitates their interactions, thereby physically enhancing signal transduction pathways. The PI-3K pathway is also required for ADCC function and can be blocked by wortmannin, a fungal metabolite that inhibits ADCC and binds covalently to the p110 subunit of PI-3K.

The PH domain-containing Vav protein and the Rho family guanine nucleotide-binding proteins (G proteins) are also involved in NK cell granule polarization required for ADCC function. Syk is involved in the phosphorylation of Vav, although the precise mechanism remains unclear.<sup>13,15</sup> The cholera toxin A subunit (Ctx-A), a known inhibitor of G proteins, can inhibit ADCC activity; however, it is unclear where exactly this inhibition occurs, as Ctx-A may also have pleiotropic effects on  $\text{IP}_3$  and GTP-binding proteins.<sup>16</sup>

For the sake of simplicity, it is tempting to limit the description of ADCC signaling mechanisms to the three Syk-related pathways outlined in Figure 1.3; however, we must bear in mind four important concepts to avoid oversimplifications or dogmatic views of the downstream signals involved in ADCC:

1. Signaling cascades do not work in isolation, and there is a considerable degree of cross-talk between Fc receptors and integrins,<sup>17</sup> surface receptors, and other intracellular proteins whose functions are still under investigation.<sup>18</sup>
2. There is a considerable degree of redundancy involving certain steps along these three pathways.
3. ADCC signaling mechanisms involving Fc $\gamma$ RI, Fc $\gamma$ RII, and Fc $\gamma$ RIIIb have yet to be